Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
10 Janvier 2022 - 2:00PM
Business Wire
Six clinical-stage molecules targeting TIGIT,
the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1
continue to advance
- Multiple datasets are expected in 2022, including presentations
planned for domvanalimab and etrumadenant in 1L PD-L1 high
non-small cell lung cancer (NSCLC; ARC-7), quemliclustat in
pancreatic cancer (ARC-8), and pharmacokinetic/pharmacodynamic data
for AB521, Arcus’s HIF-2a inhibitor
- Data from ARC-4, a randomized Phase 1/1b study in second- and
third-line EGFR-mutation positive (EGFRm+) NSCLC, did not show
differentiated clinical activity for the etrumadenant-based
combination, and this setting has been de-prioritized
- Arcus and Gilead plan to initiate several new Phase 2 and Phase
3 studies evaluating intra- and cross-portfolio combinations
targeting areas of high unmet need in 2022
- Arcus’s cash position will nearly double to $1.4 billion upon
receipt of option payments from Gilead in early Q1
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer, today
provided updates on clinical programs and key milestones
anticipated in 2022.
“Our priorities for 2022 are clear and unambiguous—to flawlessly
execute on the expansion of our global clinical programs which will
include more than 10 randomized Phase 2 and 3 studies. We also
expect to present randomized datasets from ARC-7 and ARC-8 at
medical meetings and generate early data for AB521 that will
clarify its potential as a best-in-class molecule,” said Terry
Rosen, Ph.D., Chief Executive Officer of Arcus Biosciences. “Our
strong cash position and the support from our partner Gilead
Sciences enable earlier investment to intelligently advance a broad
development plan for our novel and potentially practice-changing
combinations to treat cancer.”
Program Updates and 2022
Milestones
Anti-TIGIT program (domvanalimab and
AB308)
Recent Updates:
- Taiho Pharmaceutical Co., Ltd., exercised its option for
domvanalimab and AB308 in Japan and certain other territories in
Asia (excluding China). In exchange for the exclusive license,
Taiho will make an option exercise payment, as well as additional
payments upon achievement of clinical, regulatory and
commercialization milestones, and, if any products from the program
are approved, will pay royalties on net sales of such
products.
Anticipated 2022 Milestones:
- Data from ARC-7, an ongoing randomized 150-patient three-arm
study in first-line PD-L1≥50% NSCLC, including progression-free
survival data, are expected to be presented in 2H22.
- In addition to ARC-10, an ongoing registrational study in 1L
PD-L1≥50% NSCLC, we and Gilead plan to initiate two new Phase 3
studies in lung and gastrointestinal (GI) cancers, as well as
additional clinical studies of domvanalimab-based combinations, in
2022.
- AstraZeneca and Arcus will initiate the PACIFIC-8
registrational Phase 3 study in January to evaluate domvanalimab
plus durvalumab, an anti-PD-L1 antibody, in unresectable Stage 3
NSCLC with curative intent, where durvalumab is standard of
care.
- Data from the Phase 1/1b ARC-12 study evaluating AB308, an
Fc-enabled anti-TIGIT antibody, plus zimberelimab in advanced
malignancies will inform future development plans.
Etrumadenant (A2a/A2b adenosine
receptor antagonist)
ARC-4 Update:
- The randomized Phase 1/1b study ARC-4 did not show
differentiated clinical activity for etrumadenant plus zimberelimab
and pemetrexed/carboplatin compared to that of zimberelimab and
pemetrexed/carboplatin in patients with metastatic, EGFRm+ NSCLC
who progressed after one or more TKI therapies. Arcus is conducting
exploratory biomarker analyses to assess whether sub-populations of
patients in the study derive benefit from etrumadenant-based
treatment, such as those with PD-L1 high tumors. Final data from
the study will be presented when available.
- All ongoing studies for etrumadenant will continue unchanged.
These studies are in settings where encouraging clinical activity
has been observed, such as PD-L1≥50% NSCLC (ARC-7),
castrate-resistant prostate cancer (CRPC; ARC-6), and colorectal
cancer (CRC; ARC-9). Patients whose tumors harbor EGFRm+
characteristics are excluded from the ARC-7 and ARC-10
studies.
Anticipated 2022 Milestones:
- Data from the etrumadenant-containing arm of ARC-7 are
anticipated to be presented in 2H22, as noted above.
- Data from the randomized cohort of ARC-6 evaluating
etrumadenant plus zimberelimab and docetaxel versus docetaxel in
second-line (2L) metastatic CRPC are anticipated in 2H22.
- Additional clinical studies for etrumadenant-based
combinations, including the “triplet” of etrumadenant plus
domvanalimab and zimberelimab, are being planned for 2022.
Quemliclustat (small molecule CD73
inhibitor)
Recent Updates:
- Completed enrollment of 90 patients into the randomized portion
of ARC-8, a Phase 1 study evaluating quemliclustat plus
zimberelimab and gemcitabine/nab-paclitaxel vs quemliclustat plus
gemcitabine/nab-paclitaxel in 1L pancreatic cancer.
Anticipated 2022 Milestones:
- Results from the randomized portion of ARC-8, including data on
progression-free survival, are expected to be presented in
2H22.
- Enrollment of the cohort in 2L pancreatic cancer, an area of
high unmet need, is on track to be completed in 1H22.
- Additional clinical studies for quemliclustat are being planned
for 2022.
AB521 (HIF-2a inhibitor)
Recent Updates:
- Initiated ARC-14, a study to investigate the safety,
tolerability, and pharmacokinetic profile of AB521 in healthy
volunteers.
Anticipated 2022 Milestones
- Share pharmacokinetic and safety data from ARC-14 in 1H22,
which may demonstrate competitive advantages to other HIF-2a
inhibitors.
- Initiate Phase 1/1b study in oncology patients in
mid-2022.
Discovery Programs:
- Added a research collaboration to the existing agreement with
Gilead under which Arcus will lead the discovery and early
development of drug candidates against two novel research targets
jointly selected by the parties.
- Selected AB598 (CD39 antibody) as a development candidate,
which is advancing into IND-enabling studies; several other
oncology discovery programs continue to progress.
- In 1H22, expect to select the first development candidate for a
non-oncology target. This small molecule may have first-in-class
potential in several inflammatory diseases.
Financial Guidance
Arcus’s cash position will nearly double to $1.4 billion, upon
receiving the option payment totaling $725 million for three
programs from Gilead. With this cash position and 50/50 cost
sharing with Gilead for the joint development programs, Arcus plans
to expand its clinical development programs and anticipates cash
utilization of $275-325 million in 2022.
Arcus Clinical Study Overview
Trial
Name
Arms
Setting
Status
NCT No.
ARC-4
etruma + zim + carbo/pem vs.
zim + carbo/pem
TKI R/R EGFRmut NSCLC
Ongoing
Randomized
Phase 1/2
NCT03846310
ARC-6
etruma + zim + SOC vs. SOC
2L/3L CRPC
Ongoing
Randomized
Phase 2
NCT04381832
ARC-7
zim vs. zim + dom vs. zim +
dom + etruma
1L NSCLC (PD-L1 ≥ 50%)
Ongoing
Randomized
Phase 2
NCT04262856
ARC-8
quemli + zim + gem/nab-pac
vs. quemli + gem/nab-pac
1L PDAC
Ongoing
Randomized
Phase 1/1b
NCT04104672
ARC-9
etruma + zim + mFOLFOX
vs. SOC
2L/3L/3L+ CRC
Ongoing
Randomized
Phase 2
NCT04660812
ARC-10
chemo vs. zim vs. zim + dom
1L NSCLC (PD-L1 ≥ 50%)
Ongoing
Registrational
NCT04736173
ARC-12
AB308 + zim
Advanced Malignancies
Ongoing
Phase 1/1b
NCT04772989
ARC-14
AB521
Healthy Volunteer
Ongoing
NCT05117554
PACIFIC-8
durva ± dom
Curative-Intent Stage 3 NSCLC
Planned
Registrational
NA
Carbo/pem: carboplatin/pemetrexed; dom: domvanalimab; durva:
durvalumab; etruma: etrumadenant; gem/nab-pac:
gemcitabine/nab-paclitaxel; quemli: quemliclustat; R/R:
relapsed/refractory; SOC: standard of care; zim: zimberelimab CRC:
colorectal cancer; CRPC: castrate-resistant prostate cancer; NSCLC:
non-small cell lung cancer; PDAC: pancreatic ductal
adenocarcinoma
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well characterized biology and pathways and studying novel,
biology-driven combinations that have the potential to help people
with cancer live longer. Founded in 2015, the company has expedited
the development of six investigational medicines into clinical
studies, including new combination approaches that target TIGIT,
PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently,
HIF-2alfa. For more information about Arcus Biosciences’ clinical
and pre-clinical programs, please visit www.arcusbio.com or follow
us on Twitter.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements regarding events or results to occur in the future
contained herein, including, but not limited to, Dr. Rosen’s quote,
upcoming data presentations, trial initiations and other milestones
and the associated timing of such activities, including as set
forth under the captions “Anticipated 2022 Milestones”, Arcus’s
future development plans, and Arcus’s expectations regarding its
plans and projected cash utilization, are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements involve known and unknown risks and
uncertainties and other important factors that may cause Arcus’s
actual results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: Arcus’s dependence on the collaboration
with Gilead for the successful development and commercialization of
its optioned molecules; difficulties associated with the management
of the collaboration activities or expanded clinical programs;
difficulties or delays in initiating or conducting clinical trials
due to difficulties or delays in the regulatory process, enrolling
subjects or manufacturing or supplying product for such clinical
trials, all of which may be exacerbated by the COVID-19 pandemic;
the unexpected emergence of adverse events or other undesirable
side effects; risks associated with preliminary and interim data;
the inherent uncertainty associated with pharmaceutical product
development and clinical trials; and changes in the competitive
landscape for Arcus’s programs. Risks and uncertainties facing
Arcus are described more fully in its quarterly report on Form 10-Q
for the quarter ended September 30, 2021, filed on November 8,
2021, with the SEC. You are cautioned not to place undue reliance
on the forward-looking statements, which speak only as of the date
of this press release. Arcus disclaims any obligation or
undertaking to update, supplement or revise any forward-looking
statements contained in this press release.
The Arcus name and logo are trademarks of Arcus. All other
trademarks belong to their respective owners.
Source: Arcus Biosciences
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005358/en/
Investor and Media Inquiries: Holli Kolkey VP of
Corporate Communications (650) 922-1269 hkolkey@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Arcus Biosciences (NYSE:RCUS)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024